Abstract
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) which blocks its binding to RANK, inhibiting the development and activity of osteoclasts, followed by suppression of bone resorption. Denosumb given subcutaneously twice yearly for 3 years was associated with a reduction in the risk of vertebral, nonvertebral and hip fractures but not with serious adverse events in women with osteoporosis. New horizon would be brought about by Denosumab, new molecular targeting pharmaceutics in the treatment of osteoporosis as well as rheumatoid arthritis and metastatic bone diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
